National Center for Regenerative Medicine, NIH, Bethesda, Maryland, USA.
Stem Cells. 2012 Jan;30(1):55-60. doi: 10.1002/stem.770.
Hematopoietic cell transplantation (HCT) has become a standard practice to treat a number of malignant and nonmalignant hematologic diseases. Bone marrow, mobilized peripheral blood, and umbilical cord blood can all serve as primary sources of cells for HCT. The number of cord blood units currently stored is large, although it represents only a fraction of potential collections. With much of the collection being sequestered in private banks for possible autologous use, there is a reason to expect that public banks may not be able to provide for the demand in coming years as use of cord blood for treatment of patients with diseases such as leukemia and lymphoma continues to increase. We suggest that a possible solution to encourage private banks to share their valuable units is to apply recent methodologies to generate induced pluripotent stem cells from cord cells and to optimize techniques to generate hematopoietic lineages from them. This strategy would allow us to take advantage of the units already collected under appropriate regulatory guidelines, to access a pristine cell that can be converted to a pluripotent cell at a much higher efficiency and in a shorter time period than other cells. The ability to potentially replenish a used cord unit with new cells, as well as extend the potential utility of cord blood for additional therapeutic applications, should allow banks to develop an appropriate business model for both private and public cord blood banks to flourish.
造血细胞移植（HCT）已成为治疗多种恶性和非恶性血液疾病的标准方法。骨髓、动员外周血和脐带血均可作为 HCT 的细胞主要来源。目前储存的脐带血单位数量很大，尽管这只代表了潜在采集量的一部分。由于大部分采集都被私人银行封存，以备可能的自体使用，因此有理由预计，随着脐带血在治疗白血病和淋巴瘤等疾病中的应用不断增加，未来几年，公共银行可能无法满足需求。我们建议，鼓励私人银行共享其有价值的单位的一个可能的解决方案是应用最近的方法从脐带细胞中生成诱导多能干细胞，并优化从它们生成造血谱系的技术。这种策略将使我们能够在适当的监管指导下利用已经收集的单位，利用可以转化为多能细胞的原始细胞，其效率比其他细胞更高，时间更短。有可能用新细胞补充已使用的脐带单位，并为脐带血的其他治疗应用扩展潜在用途，这应该使银行能够为私人和公共脐带血库制定合适的商业模式，以实现繁荣发展。
